Q2 2023

Filed Aug 9, 2023 · 10-Q · 40 days after period end · 0000950170-23-040598

Q2 2023 · 10-Q

Revenue

$0.00

no prior Q2 2022 on file

Net Income

-$12.34M

N/M vs Q2 2022

EPS Diluted

-$0.22

N/M vs Q2 2022

Operating Income-$13,558,000N/M

Operating Cash Flow

Same quarter

Metric	Q2 2023	Q2 2022	Q2 2021	Q2 2020
Revenue	$0.00	—	—	$189.00K
Net Income	-$12.34M	-$12.42M	-$10.39M	-$6.45M
EPS Diluted	-$0.22	-$0.44	-$0.64	-$0.69

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

aTYR PHARMA INC · CIK 1339970 · Engraved from SEC EDGAR